Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)

Launched by AJOU UNIVERSITY SCHOOL OF MEDICINE · Feb 11, 2014

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with unstable angina or non-ST elevation myocardial infarction
• • 2. Patients who are planned coronary angiography
• • 3. Age \>18 years, \<75 years
• • 4. Patients who agree to the study protocol
• Exclusion Criteria:
• • 1. Recent treatment with clopidogrel or pletaal or glycoprotein IIb/IIIa Rc antagonist
• • 2. Active bleeding (peptic ulcer, trauma or intra-cranial hemorrhage)
• • 3. Allergy to antiplatelet agent
• • 4. Bleeding diasthesis (blood coagulation disorders, uncontrolled severe hypertension, history of severe bleeding)
• • 5. History of drug abuse or alcohol abuse
• • 6. ST elevation myocardial infarction
• • 7. Pregnancy
• • 8. Low platelet count (\< 100,000 /L) or abnormal results of PT or PTT
• • 9. Liver disease ( bilirubin \> 2 mg/dL, AST or ALT \> 100 IU)
• • 10. Renal failure ( Cr \> 2.0 mg/dL)
• • 11. Malignancy
• • 12. Proton pump inhibitor, NSAIDs statin (except atorvastatin)